Pros | - | 5Y returns in the top 25% of the category. 3Y returns in the top 25% of the category. Among most bought funds within the category. | ||
Cons | - | - |
INDMoney rank | - | 3/8 | ||
Category,Subcateogry | Equity,Sector - Healthcare | Equity,Sector - Healthcare | ||
Fund Age | 0 Years | 7 Years | ||
Fund Size | 322 Cr | 6227 Cr | ||
Min Investment | SIP ₹500 Lumpsum ₹500 | SIP ₹100 Lumpsum ₹5000 | ||
Expense Ratio | 0.73% | 1.03% | ||
Exit Load | 1% | 1% | ||
Benchmark Index | BSE Healthcare TR INR | BSE Healthcare TR INR |
No of Holdings | 44 | 43 | ||
Top 5 Holdings | Divi's Laboratories Ltd (7.75%) Sun Pharmaceuticals Industries Ltd (7.53%) Apollo Hospitals Enterprise Ltd (6.29%) Cipla Ltd (5.45%) Fortis Healthcare Ltd (3.83%) | Sun Pharmaceuticals Industries Ltd (11.58%) Dr Reddy's Laboratories Ltd (9.1%) Divi's Laboratories Ltd (8.75%) Aurobindo Pharma Ltd (8.25%) Cipla Ltd (6.92%) | ||
No of Sectors | 4 | 3 | ||
Top 3 Sectors | Health (89.81%) Consumer Defensive (7.43%) Basic Materials (2.22%) | Health (97.7%) Basic Materials (1.18%) Financial Services (1.12%) | ||
Equity % | 98.7% | 97.55% | ||
Debt % | - | - | ||
P/E | 38.48 | 30.65 | ||
P/B | 5.21 | 4.17 | ||
Credit Quality | - | - | ||
Modified Duration | - | - | ||
YTM | - | - |
1-Month Return | 4.24% | 3.81% | ||
3-Month Return | -1.38% | -2.44% | ||
6-Month Return | 7.62% | 8.59% | ||
1-Year Return | - | 7.23% | ||
3-Year Return | - | 28.6% | ||
5-Year Return | - | 21.94% |
Sharpe | - | 1.24 | ||
Alpha | - | 4.3 | ||
Beta | - | 0.95 | ||
Standard Deviation | - | 15.67 | ||
Information Ratio | - | 1.4 |
Description | Bajaj Finserv Healthcare Fund Direct Growth is an equity fund.The fund could potentially beat inflation in the long-run. | ICICI Prudential Pharma Healthcare and Diagnostics (P.H.D) Fund Direct Growth is an equity fund.The fund could potentially beat inflation in the long-run. | ||
Managers | Sorbh Gupta,Nimesh Chandan,Siddharth Chaudhary | Dharmesh Kakkad,Sharmila D’mello |